Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_assertion type Assertion NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_head.
- NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_assertion description "[Because the humanized anti-CD20 antibody, rituximab, has antitumor activity in patients with PTLD and stimulates apoptosis in some lymphoid cell lines, we sought to determine whether Bcl-2 antisense treatment potentiates the antitumor effects of rituximab in EBV-associated lymphoproliferative disease in vitro and in vivo.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_provenance.
- NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_assertion evidence source_evidence_literature NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_provenance.
- NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_assertion SIO_000772 12738752 NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_provenance.
- NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_assertion wasDerivedFrom befree-20150227 NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_provenance.
- NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_assertion wasGeneratedBy ECO_0000203 NP911204.RAKyccfk9IprRFad0x_OPPRX-2ICECttiPtLtRHloUHf0130_provenance.